Allos Therapeutics to Announce 2006 Third Quarter Financial Results on Friday, November 3

WESTMINSTER, Colo., Nov. 1  /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (NASDAQ:ALTH), today announced that it will report its 2006 third quarter financial results on Friday, November 3, 2006, before the open of the U.S. financial markets.

Paul L. Berns, President and Chief Executive Officer, and other members of Allos' senior management will provide a company update and summary of third quarter results via webcast and conference call on Friday, November 3, 2006 at 11:00 AM ET.  The dial in number for U.S. residents to participate is 877-407-8031.  International callers should dial 201-689-8031.  Participants should reference the Allos Therapeutics conference call.  An audio replay of the conference call will be available from 5 PM ET on Friday, November 3, 2006, until 11:59 PM ET on Friday, November 10, 2006.  To access the replay, please dial 877-660-6853 (domestic) or 201-612-7415 (international); Replay pass codes (both required for playback): account # 286; conference ID # 218565.  The webcast of this call will be available from the homepage and the investors/media section of the Company's web site, http://www.allos.com/ and will be archived for 30 days.

About Allos Therapeutics, Inc.

Allos Therapeutics, Inc. (ALTH) is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer.  The Company has two product candidates in late-stage clinical development: EFAPROXYN(TM) (efaproxiral), a radiation sensitizer currently under evaluation in a pivotal Phase 3 trial in women with brain metastases originating from breast cancer, and PDX (pralatrexate), a novel, next generation antifolate currently under evaluation in a pivotal Phase 2 trial in patients with relapsed or refractory peripheral T-cell lymphoma.  The Company is also evaluating RH1, a targeted chemotherapeutic agent, in a Phase 1 trial in patients with advanced solid tumors.  For additional information, please visit the Company's website at http://www.allos.com/.

Safe Harbor Statement

The 2006 third quarter results press release and conference call will contain forward-looking statements that involve significant risks and uncertainties, including those that can be found in the "Risk Factors" section of Allos' Form 10-K for the year ended December 31, 2005 and in Allos' periodic reports on Form 10-Q and Form 8-K.  Allos is providing the information contained in the press release and conference call as of the date of the release and does not undertake any obligation to update any forward- looking statements as a result of new information, future events or otherwise. The Company cautions investors not to place undue reliance on the forward- looking statements contained in the press release or the conference call.  No forward-looking statement can be guaranteed and actual events and results may differ materially from those projected. 

DATASOURCE: Allos Therapeutics, Inc.



CONTACT:  Jennifer Neiman, Corporate Communications of Allos

Therapeutics, Inc., [phone], 



Web site:  http://www.allos.com/

Copyright